We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toNew-FDA-Draft-Guidance-on-Part-11-in-Clinical-Investigations

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.


New FDA Draft Guidance on Part 11 in Clinical Investigations

    Session Chair(s)
      Ron D. Fitzmartin, DIAFellow, PhD, MBA

      Ron D. Fitzmartin, DIAFellow, PhD, MBA

      • Senior Advisor, Office of Strategic Programs, CDER
      • FDA, United States
    In 1997, FDA published a final rule (21 CFR Part 11) to establish criteria that must be met when a record required by predicate rule is created, modified, maintained, archived, retrieved, or transmitted in electronic form. In 2003 the FDA published the final guidance on the scope and applications of Part 11. The final guidance provided for a narrow and practical interpretation of Part 11. In June 2017 FDA issued a new draft guidance on the use of electronic records and electronic signatures in clinical investigations under 21 CFR Part 11. This guidance is the first look at Part 11 since the 2003 Scope and Applications guidance. The guidance acknowledges that technology has progressed significantly and that FDA should clarify the Part 11 controls that sponsors and regulated entities must implement, as appropriate, in the current technological environment. The goal of the new guidance is to describe how FDA intends to exercise enforcement discretion with regard to certain Part 11 requirements during the re-examination of Part 11.

    This session will review the new guidance, the public comments, discuss next steps and hear from the audience on the topics presented.
    Learning Objective : Describe the new 21 CFR Part 11 guidance in clinical investigations; Evaluate the purpose of the new Part 11 guidance; Identify the key components of the guidance.
    Speaker(s)
      Leonard  Sacks, MD

      Panelist

      Leonard Sacks, MD

      • Associate Director for Clinical Methodology, Office of Medical Policy, CDER
      • FDA, United States
      Cheryl A. Grandinetti, PharmD

      Panelist

      Cheryl A. Grandinetti, PharmD

      • Health Scientist, Policy Analyst, OSI, OC, CDER
      • FDA, United States